ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Methylglyoxal Affects Dopamine Homeostasis in SH-SY5Y Cells Through the Modulation of miR-190a and miR-214.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research Progress on Pathology, Molecular Mechanisms, and Intervention Strategies of Cognitive Dysfunction Associated with Type 2 Diabetes.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Dopamine (DA) homeostasis is crucial for several relevant body functions, including cognition. Diabetes mellitus (DM) is characterized by both cognitive decline and dopaminergic dysfunction. Methylglyoxal (MGO), a reactive neurotoxic dicarbonyl, which accumulates in DM, induces dopaminergic dysfunction, contributing to DA depletion, and is associated with cognitive deficit. However, the molecular mechanisms underlying MGO impact on dopaminergic function are still unknown. This study aims to clarify how MGO damages the dopaminergic system, analyzing the contribution of miRNAs in its deleterious effect in SH-SY5Y cells. We found that treatment with MGO significantly reduces the intracellular DA content, increasing the expression of proteins known to negatively affect DA amount, such as COMT (Catechol-O-methyltransferase), MAO (Monoamine oxidase), and α-Syn (α-synuclein), encoded by the SNCA gene. This was paralleled by a significant reduction in the expression of miR-190a and miR-214, known to be regulated by MGO in other cellular models. We found, by TARGETSCAN analysis, that these two miRNAs are predicted regulators of COMT and SNCA. Gain- and loss-of-function experiments highlighted that these miRNAs are able to modulate the expression of these proteins. We also showed that COMT is a direct target of both miR-190a and miR-214, while SNCA is a direct target of miR-190a and an indirect target for miR-214. Importantly, the transfection of miR-190a and miR-214 specific mimics reverted MGO effects on COMT and α-Syn expression and restored DA intracellular content. Thus, these miRNAs could represent innovative pharmacological targets for the treatment of DM-associated dopaminergic dysfunction and cognitive decline.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.